DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
– Webcast of Earnings Call Today, November 13th at 4:30 p.m. ET
– Topline data from AHFIRM trial showed compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days
Related news for (DRRX)
- DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health
- MoBot alert highlights: NASDAQ: ATNF, NASDAQ: DRRX, NASDAQ: AEHL, NASDAQ: NTHI, NASDAQ: NIVF (07/29/25 09:00 AM)
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/29/25 07:00 AM
- DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
- DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update